Planning to commercialize your biomarker invention?

Thousands of candidate biomarkers are being discovered and the number of publications has exploded in recent years, but the discovery of a candidate biomarker is just the beginning of a long road to a commercial product.

Few findings enter to the specific assay development phase, pass the evaluation of analytical and clinical performance characteristics, and are eventually transformed into IVD assays, as biomarker development and commercialization is complicated, time consuming and expensive.

Visit the BIC Project Website now!

Connect to your clients in North-West Europe!

Boost4Health provided support to small and medium-sized enterprises (SMEs) who wish to explore their international growth potential. For instance: expand their international network, find expertise abroad or validate products in another market.

Visit the Boost4Health website now!

The BeYond-COVID project aims to make COVID-19 data accessible to scientists in laboratories but also to anyone who can use it, such as medical staff in hospitals or government officials. Going beyond SARS-CoV-2 data, the project will provide a framework for making data from other infectious diseases open and accessible to everyone.

BY-COVID CORE ACTIVITIES

Mobilising data: Ensuring data from around the world can easily be submitted to core data hubs.

Connecting data: Linking infectious disease data. For instance, clinical data with viral data.

Standardising data: Providing recommended data management best practices and standards for describing data.

Exposing and analysing data: Providing data analysis methods and protocols.

Visit the BY-COVID website now!

CELIS is one of 13 European Strategic Cluster Partnerships for Excellence (ESCP-4x) selected under the European Cluster Excellence Programme as part of the European Commission’s COSME programme.
CELIS combines some of the world-class life science ecosystems in Europe: BioRN Life Science Cluster Rhine Neckar (Germany), Smart Hub Flemish-Brabant (Belgium), Biopeople: Denmark's Life Science Cluster (Denmark) and Tartu Biotechnology Park (Estonia).

The project helps clusters, networks and business and innovation support organisations to maximize opportunities linked to cross-sectoral and inter-regional cooperation and internationalisation. It offers them and their members unique opportunities to expand their relationships and to enhance public-private partnerships.

CELIS CORE ACTIVITIES

• Twinning, networking, and joint collaboration activities to support SMEs (EventXchange) in the field of digitalisation, biomarkers, nano-electronics and multi-omics in the life sciences [more]
• Financial support for short-term exchanges within Europe: ClusterXchange. The ClusterXchange programme is a new pilot programme to financially support short-term exchanges to better connect Europe’s industrial ecosystems. [more]
• Cluster management skill development to boost excellence in delivering SME support

Visit the CELIS website now!

DIGI-B-CUBE

Lead by Oslo Cancer Cluster, the DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining Artificial Intelligence (AI), Cognitive Computing Digital Technologies (CCDT) with the Bioimaging-Biosensing-Biobanking (B-CUBE) industries to deliver market sensitive disruptive technologies and generating innovative solutions that enhance patient-centred diagnostic work-flows, delivered through the improved algorithms for Medical Diagnostics’ efficiency and accuracy.

Visit the DIGI-B-CUBE website now!

Developing cross-border partnerships to boost innovation in advanced MATerials for MEDical applications

Are you a health SME, looking to accelerate your innovation within the fields of Advanced Materials and Medical Devices? MATMED is your project!

MATMED supports SME innovations through different services:

• Online platform to match with a MATMED partner or a service provider, that can help develop your innovation.
• Acceleration Programme:
  • €12,500 vouchers to reach TRL 4-5;
  • €25,000 vouchers to reach TRL 6-7.
• Private investment - Matchmaking events to connect you with specialised investors.
• Regulatory workshops, to adapt your company to the new EU Medical Device Regulations (2017/745 and 2017/746).

Interested? You can register for free at www.matmed.eu!  

SAPHIRe

SAPHIRe is a 3.5-year project (2019-2022) managed by a consortium consisting of the department of Economy, Science and Innovation of the Flemish Government, the Public Health Agency of Northern Ireland, EIT Health/InnoStars and EuroBioForum Foundation. It aims to structure the application of personalised health at regional level which will drive the transition towards sustainable healthcare and personalised health. To realise this goal the consortium mapped personalised medicine and health policies in European regions, to understand barriers, gaps and to identify good practices. There was also a special emphasis on remote and sparsely populated regions and regions with limited resources, innovation and/or absorption capacity to ensure access to advanced developments in this field for all.

Visit the SAPHIRe website now!

Vanguard Initiative Smart Health

The Vanguard Initiative (VI) is an initiative of European regions seeking to influence the European political agenda. The initiative’s vision is that inter-regional collaboration to develop new, innovative value chains is essential to accelerate the uptake of innovative technologies and thereby provide solutions to the societal challenges facing European regions. VI has developed a methodology (learn – connect – demonstrate – commercialize) to facilitate and accelerate this type of collaboration. In 2021 the VI Smart Health pilot was launched. This pilot will bring the agenda to implement personalised medicine to the next level while transforming the connected European industrial value chains. The partner regions already established solid ecosystems combining biomedical, technological and data-driven expertise. By bringing these ecosystems together, a higher added value will be reached and boost the implementation of personalised medicine. It will realise an innovative approach for health and care in Europe.

Visit the Vanguard Initiative Smart Health website now!

Biobank Graz

Biobank Graz is one of the largest and most well-known clinical biobanks in the world. Around 20 million individual specimens of body fluids and human tissue are stored here. Biobank Graz allows access to these specimens and associated data for scientific research purposes. The common goal is to develop approaches to diagnosing and treating disease.

Biobank Graz is a central service institution of the Medical University of Graz that supports biomedical research by collecting, processing and storing high-quality biological specimens and associated data. Biobank Graz works closely with academic and industrial research partners while building up specific cohorts, operating basic collections and making the specimens along with associated anonymized/pseudonymized data available for research projects. See full specimen collection.

Please find their homepage here.

BBMRI-ERIC

Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium, the pan-European infrastructure of national biobank networks (Homepage).

• European research infrastructure for biobanking
• Bringing together all the main players from the biobanking field – researchers, biobankers, industry, and patients to boost medical research.
• Quality management services
• Support with ethical, legal and societal issues
• IT services:
  • Directory
    • Intended for all different types of users, providing aggregate information about biobanks and their sample/data collections.
  • Negotiator
    • Facilitating communication between researchers searching for samples/data and biobanks allowing refinmenet of their queries and once the search is done, to request samples
  • Locator
    • A tool for researchers looking for samples/data, enabling them to query available samples/data sets on the level of individual samples and/or data items, under development.
    • NOT a search tool for individual samples.

BBMRI.be is the Belgian National Node of the European biobank infrastructure BBMRI-ERIC.

The BBMRI.be network connects 18 Belgian biobanks that are linked to public institutions such as hospitals, universities and research centers. The BBMRI.be network offers not only samples and data but also expertise on several biobank topics including ethical-legal, quality and IT issues. More information about the network can be found on the homepage: https://www.bbmri.be/

• Samples and/or data needed? The collections of the BBMRI.be biobanks can be consulted in the online Directory: https://directory.bbmri.be/ . Due to the link with the Negotiator of BBMRI-ERIC, researchers looking for samples can also easily negotiate with our different biobanks about sample/data requests.
• Expertise needed? Do you have a question about the Belgian biobank Law, the notification of your biobank, the new biobank ISO standard (ISO 20387) or other biobank related questions, don’t hesitate to contact us at BBMRIbe@kankerregister.org.
• Looking for collaboration? BBMRI.be welcomes all Belgian biobanks with translational research potential  as well as biobank users that are seeking structural research collaborations with the BBMRI.be network to join the BBMRI.be network. 

FINBB, as a member of BBMRI-ERIC, is a one-accessshop for effortless access to Finnish biobank materials and biodata:

Fingenious is a

• Digital gateway to Finnish biobanks and biomedical research
• Built to serve academic and industry researchers and to advance medical research globally
• Provides a view of and access to biospecimens and data from all public biobanks in Finland, through a single point of contact

Feasibility and access costs (FINBB)

• Initial feasibility service is free of charge.
• Providing cost-estimation for the feasibility report if compiling the feasibility report requires exceptional effort and a significant amount of time
• Submitting access requests through Fingenious is also free of charge. Questioner will receive a cost estimation of your biobank project during the feasibility and access request

Please find their homepage here.

In.vent Diagnostica GmbH

• Partner of all diagnostic Stakeholders for the procurement of biologic material of human origin (e.g., innovations, research, development, clinical studies, production, controls, standardisation, ...)
• Active in the field of diagnostics
• Targeted procurement of human biomaterials:
  • Standards & controls – high volumes possible
  • Quality control panels
  • Clinically defined samples
    • Highly specific parameters possible
    • Samples suitable for Clinical Performance Studies
    • Extensive global network of physicians and hospitals
• Company owned study centre:
  • on demand blood donations
  • control over all steps of pre-analytics
• Clinical services: Planning, Ethics, Samples, Performance Studies, Statistics, Reports (PER), Submission at NB